A combination of an initial tumor biopsy assessing PD-L1, TMB, and ECM status, and baseline and longitudinal assessment of ECM biomarkers in the circulation may have unique potential for patient phenotyping for ICIs. The gene discussed is CD274; the disease is neoplasm.